BECTON, DICKINSON AND COMPANY

(BDX)
  Report
Delayed Nyse  -  04:00 2022-08-09 pm EDT
255.30 USD   -0.26%
08/09BECTON DICKINSON & CO : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
08/08BECTON DICKINSON AND : Announces Tender Offers for Outstanding Debt Securities - Form 8-K
PU
08/08BECTON DICKINSON & CO : Other Events (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Becton, Dickinson Unveils Combination Assay for COVID-19, Other Respiratory Viruses

06/30/2022 | 03:49am EDT


© MT Newswires 2022
All news about BECTON, DICKINSON AND COMPANY
08/09BECTON DICKINSON & CO : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
08/08BECTON DICKINSON AND : Announces Tender Offers for Outstanding Debt Securities - Form 8-K
PU
08/08BECTON DICKINSON & CO : Other Events (form 8-K)
AQ
08/08BD Announces Tender Offers for Outstanding Debt Securities
PR
08/08BECTON, DICKINSON AND COMPANY : SEC Filing 8K
CO
08/04BECTON DICKINSON & CO Management's Discussion and Analysis of Financial Condition and ..
AQ
08/04SECTOR UPDATE : Health Care Stocks Mixed Pre-Bell Thursday
MT
08/04Becton, Dickinson and Company Seeks M&A
CI
08/04TRANSCRIPT : Becton, Dickinson and Company, Q3 2022 Earnings Call, Aug 04, 2022
CI
08/04Becton Dickinson Raises FY22 Guidance
DJ
More news
Analyst Recommendations on BECTON, DICKINSON AND COMPANY
More recommendations
Financials (USD)
Sales 2022 18 822 M - -
Net income 2022 1 866 M - -
Net Debt 2022 13 567 M - -
P/E ratio 2022 37,3x
Yield 2022 1,48%
Capitalization 72 810 M 72 810 M -
EV / Sales 2022 4,59x
EV / Sales 2023 4,38x
Nbr of Employees 75 000
Free-Float 77,6%
Chart BECTON, DICKINSON AND COMPANY
Duration : Period :
Becton, Dickinson and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BECTON, DICKINSON AND COMPANY
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 255,30 $
Average target price 274,67 $
Spread / Average Target 7,59%
EPS Revisions
Managers and Directors
Thomas E. Polen Chairman, President & Chief Executive Officer
Christopher J. DelOrefice Chief Financial Officer & Executive Vice President
William R. Sigmund Chief Medical Officer & Executive Vice President
Jerry Flasz Chief Information Officer & EVP-Global Services
Elizabeth McCombs Chief Technology Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
BECTON, DICKINSON AND COMPANY3.88%72 810
ABBOTT LABORATORIES-23.33%188 974
MEDTRONIC PLC-10.00%123 703
HOYA CORPORATION-15.37%38 679
SARTORIUS STEDIM BIOTECH-23.42%34 827
DEXCOM, INC.-36.59%33 417